Carlyle Group Inc (CG) Stock Price Today
Aura AI Summary
Key Stats
- $14.08BMarket Cap
- 2,548,698Volume
- FinancialsSector
- $66.1252W High
- $39.4252W Low
- 113 DaysTypical Hold Time
- $26.44BEnterprise Value
- 3.54%Div Yield
- -Trading Activity
Track Carlyle Group Inc (CG) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Carlyle Group Inc has traded between a low of $39.42 and a high of $66.12, highlighting its annual price range. Buy and sell Carlyle Group Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Most Recent News
AST SpaceMobile COO sells 12,000 shares worth $707K after 47% gain in one year
AST SpaceMobile's Chief Operating Officer sold 12,000 shares valued at $707,000 amid the company's stock rising 47% over the past year. This insider sale could indicate profit-taking after significant gains. Investors may watch for further insider ac...

Gold breaks key support, signaling stronger bearish trend and potential further declines.
Gold prices fell below critical support levels, including the 61.8% Fibonacci retracement and the 50-day moving average, confirming renewed selling pressure and a bearish trend. The breakdown triggered aggressive selling, with subsequent support zone...

uniQure shares drop 37% after mixed results in Huntington's gene therapy trial
uniQure's stock fell sharply by 37% following a four-year update on its AMT-130 gene therapy for Huntington's disease, which showed reduced effectiveness from 80% at three years to 44% at four years, failing to reach statistical significance. Despite...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.